Although the findings in the OPTiM study demonstrated that both T-VEC and GM-CSF were well tolerated, without any treatment-related death events [32], previous studies described flu-like symptoms such as pyrexia, chills, and fatigue as the most common adverse events with T-VEC treatment [33, 34]. The gene discussed is CSF2; the disease is Fever.